Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has issued an announcement.
Qyuns Therapeutics Co., Ltd. has announced its 2024 Annual General Meeting, scheduled for June 20, 2025. The meeting will address several key resolutions, including the approval of the company’s annual reports, profit distribution plan, and remuneration scheme for directors and supervisors. Additionally, the company plans to engage KPMG as its auditor and seeks approval for amendments to its Articles of Association and related procedural rules. A special resolution will also be considered to grant the Board a mandate to issue additional H Shares, potentially impacting the company’s market operations and shareholder value.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company is primarily focused on developing therapeutic solutions and is listed on the Stock Exchange of Hong Kong.
YTD Price Performance: 51.76%
Average Trading Volume: 144,810
Technical Sentiment Signal: Hold
Learn more about 2509 stock on TipRanks’ Stock Analysis page.